E Grube

Summary

Publications

  1. ncbi request reprint Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry
    Lutz Buellesfeld
    Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 66:173-7. 2005
  2. ncbi request reprint [Percutaneous aortic valve replacement]
    Eberhard Grube
    Medizinische Klinik Kardiologie und Angiologie, HELIOS Klinikum Siegburg, Ringstrasse 49, 53721 Siegburg
    Herz 31:694-7. 2006
  3. ncbi request reprint Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: a multicenter prospective registry of 150 consecutive patients
    Carlo Di Mario
    Catheterization Laboratory, Royal Brompton Hospital, Sydney Street, London, UK
    Catheter Cardiovasc Interv 69:416-24. 2007
  4. doi request reprint Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial
    Marcus Wiemer
    Department of Cardiology, Heart and Diabetes Center North Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
    Catheter Cardiovasc Interv 75:997-1003. 2010
  5. doi request reprint The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions
    Eberhard Grube
    Department of Cardiology, University Hospital Bonn, Bonn, Germany
    Am Heart J 163:867-875.e1. 2012
  6. ncbi request reprint Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study
    Eberhard Grube
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    Circulation 114:1616-24. 2006
  7. doi request reprint Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Revalving system
    Eberhard Grube
    Departments of Cardiology, Cardiac Surgery, and Anaesthesiology, HELIOS Heart Center Siegburg, Ringstrasse 49, Siegburg, Germany
    Circ Cardiovasc Interv 1:167-75. 2008
  8. ncbi request reprint TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions
    Eberhard Grube
    HELIOS Heart Center, Department of Cardiology Angiology, Ringstrasse 49, 53721, Siegburg, Germany
    EuroIntervention 4:572-7. 2009
  9. ncbi request reprint Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results
    Eberhard Grube
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    EuroIntervention 4:71-6. 2008
  10. ncbi request reprint Paclitaxel-eluting stents: current clinical experience
    Eberhard Grube
    Heart Center Siegburg, Siegburg, Germany
    Am J Cardiovasc Drugs 4:355-60. 2004

Collaborators

Detail Information

Publications88

  1. ncbi request reprint Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry
    Lutz Buellesfeld
    Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 66:173-7. 2005
    ..The quantitative angiographic analysis revealed beneficial results with respect to the efficacy surrogates binary restenosis rate and late loss...
  2. ncbi request reprint [Percutaneous aortic valve replacement]
    Eberhard Grube
    Medizinische Klinik Kardiologie und Angiologie, HELIOS Klinikum Siegburg, Ringstrasse 49, 53721 Siegburg
    Herz 31:694-7. 2006
    ..However, the strict inclusion criteria for both procedures limit the number of potential candidates. New devices are currently under development, which will allow for a broader use of percutaneous valve replacement in the near future...
  3. ncbi request reprint Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: a multicenter prospective registry of 150 consecutive patients
    Carlo Di Mario
    Catheterization Laboratory, Royal Brompton Hospital, Sydney Street, London, UK
    Catheter Cardiovasc Interv 69:416-24. 2007
    ..The aim of the study was the assessment of the clinical, angiographic and procedural characteristics correlated with freedom from adverse events at 1 year in a real life setting of consecutive bifurcation lesions...
  4. doi request reprint Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial
    Marcus Wiemer
    Department of Cardiology, Heart and Diabetes Center North Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
    Catheter Cardiovasc Interv 75:997-1003. 2010
    ..However, long-term follow-up data are scarce and only available for sirolimus- and paclitaxel-eluting stents...
  5. doi request reprint The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions
    Eberhard Grube
    Department of Cardiology, University Hospital Bonn, Bonn, Germany
    Am Heart J 163:867-875.e1. 2012
    ..Our main aim was to evaluate the angiographic efficacy of XIENCE V (everolimus-eluting stent, or EES) in diabetic patients compared with TAXUS Liberté (paclitaxel-eluting stent, or PES)...
  6. ncbi request reprint Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study
    Eberhard Grube
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    Circulation 114:1616-24. 2006
    ....
  7. doi request reprint Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Revalving system
    Eberhard Grube
    Departments of Cardiology, Cardiac Surgery, and Anaesthesiology, HELIOS Heart Center Siegburg, Ringstrasse 49, Siegburg, Germany
    Circ Cardiovasc Interv 1:167-75. 2008
    ..This study was intended to provide a summary of the development and current safety and efficacy status of the self-expanding CoreValve Revalving prosthesis...
  8. ncbi request reprint TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions
    Eberhard Grube
    HELIOS Heart Center, Department of Cardiology Angiology, Ringstrasse 49, 53721, Siegburg, Germany
    EuroIntervention 4:572-7. 2009
    ..To assess the long-term safety and efficacy of the paclitaxel-eluting TAXUS moderate-release (MR) investigation-only stent for the treatment of long, complex coronary artery lesions...
  9. ncbi request reprint Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results
    Eberhard Grube
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    EuroIntervention 4:71-6. 2008
    ....
  10. ncbi request reprint Paclitaxel-eluting stents: current clinical experience
    Eberhard Grube
    Heart Center Siegburg, Siegburg, Germany
    Am J Cardiovasc Drugs 4:355-60. 2004
    ..Programs like these are vital to sufficiently monitor patients who have received a drug-eluting stent, particularly because of the controversy regarding long-term effects...
  11. ncbi request reprint [Surgical or interventional aortic valve repair? Pro interventional repair]
    E Grube
    HELIOS Klinikum Siegburg, Medizinische Klinik Kardiologie Angiologie, 53721 Siegburg
    Dtsch Med Wochenschr 133:2021. 2008
  12. ncbi request reprint High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial
    Eberhard Grube
    J Am Coll Cardiol 44:1368-72. 2004
    ..Santa Clara, California/Boston Scientific Corp., Natick, Massachusetts) versus uncoated control stents (n = 140) in focal, de novo coronary lesions...
  13. ncbi request reprint First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis
    Eberhard Grube
    Department of Cardiology, Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 66:465-9. 2005
    ..7 cm2). Surgical valve replacement had been declined for the patient because of comorbidities, including previous bypass surgery...
  14. ncbi request reprint TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions
    Eberhard Grube
    HELIOS Heart Center Siegburg, Siegburg, Germany
    Eur Heart J 28:2578-82. 2007
    ..In order to assess the long-term safety and clinical efficacy of the polymer-based moderate release (MR) paclitaxel-eluting TAXUS MR stent in treatment of complex lesion subsets, we evaluated the 2-year follow-up of TAXUS VI...
  15. ncbi request reprint Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings
    Eberhard Grube
    HELIOS Heart Center, Siegburg, Germany
    Am J Cardiol 99:1691-7. 2007
    ..In conclusion, the Axxess Plus conical stent effectively treats bifurcation lesions alone or in conjunction with other drug-eluting stents...
  16. ncbi request reprint BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease
    Eberhard Grube
    HELIOS Heart Center Siegburg, Department of Cardiology Angiology, Ringstrasse 49, 53721 Siegburg, Germany
    Expert Rev Med Devices 3:731-41. 2006
    ..Clinical studies have demonstrated the BioMatrix to be well tolerated and effective, and it has now become the subject of an aggressive clinical program...
  17. doi request reprint A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent
    Eberhard Grube
    HELIOS Heart Center, Siegburg, Germany
    JACC Cardiovasc Interv 3:431-8. 2010
    ....
  18. ncbi request reprint Drug eluting stents: initial experiences
    E Grube
    Heart Center Siegburg Ringstrasse 49 53721 Siegburg, Germany
    Z Kardiol 91:44-8. 2002
    ....
  19. ncbi request reprint Drug-eluting stents: clinical experiences and perspectives
    E Grube
    Heart Center Siegburg, Siegburg, Germany, Italy
    Minerva Cardioangiol 50:469-73. 2002
    ..Nevertheless, we need more trials and an agreement of definitions in order to evaluate this treatment concept and eliminate unwanted side-effects...
  20. ncbi request reprint Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection
    E Grube
    Department of Cardiology Angiology, Heart Center Siegburg, Siegburg, Germany
    Circulation 104:2436-41. 2001
    ..This report details the first clinical experience of the effectiveness and safety of an emboli protection system in 11 SVG lesions and 15 native coronary artery lesions...
  21. doi request reprint Feasibility of transcatheter aortic valve implantation without balloon pre-dilation: a pilot study
    Eberhard Grube
    Department of Medicine II, University Hospital Bonn, Bonn, Germany
    JACC Cardiovasc Interv 4:751-7. 2011
    ..The purpose of this pilot study was to evaluate the feasibility and safety of transcatheter aortic valve implantation (TAVI) without balloon pre-dilation...
  22. doi request reprint The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions
    Eberhard Grube
    Department of Cardiology, University Hospital Bonn, Bonn, Germany
    JACC Cardiovasc Interv 4:168-75. 2011
    ....
  23. ncbi request reprint Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome
    Eberhard Grube
    HELIOS Heart Center Siegburg, Siegburg, Germany
    J Am Coll Cardiol 50:69-76. 2007
    ..We sought to determine both the procedural performance and safety of percutaneous implantation of the second (21-French [F])- and third (18-F)-generation CoreValve aortic valve prosthesis (CoreValve Inc., Irvine, California)...
  24. ncbi request reprint Images in cardiovascular medicine. Intracoronary imaging with optical coherence tomography: a new high-resolution technology providing striking visualization in the coronary artery
    Eberhard Grube
    Department of Cardiology Angiology, Heart Center Siegburg, Siegburg, Germany
    Circulation 106:2409-10. 2002
  25. ncbi request reprint Initial experience with paclitaxel-coated stents
    Eberhard Grube
    Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    J Interv Cardiol 15:471-5. 2002
    ....
  26. ncbi request reprint TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions
    Eberhard Grube
    Department of Cardiology Angiology, Heart Center Siegburg, Siegburg, Germany
    Circulation 107:38-42. 2003
    ..The TAXUS I trial was the first in-human experience evaluating safety and feasibility of the TAXUS NIRx stent system compared with bare NIR stents (control) (Boston Scientific Corp) for treatment of coronary lesions...
  27. ncbi request reprint Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer
    Eberhard Grube
    Heart Center Siegburg, Siegburg, Germany
    Circulation 109:2168-71. 2004
    ....
  28. ncbi request reprint Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I
    L Büllesfeld
    Abt für Kardiologie Angiologie, Krankenhaus and Herzzentrum Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    Z Kardiol 92:825-32. 2003
    ..Therefore, this stent design seems to be safe and effective, even in long-term follow-up...
  29. ncbi request reprint Comparative endoluminal visualization of TAXUS crush-stenting at 9 months follow-up by intravascular ultrasound and optical coherence tomography
    L Buellesfeld
    Department of Cardiology Angiology, Heart Center Siegburg, Ringstrasse 49, 53721, Siegburg, Germany
    Z Kardiol 94:690-4. 2005
    ..Compared to IVUS, OCT proved the coverage of the stent struts adjacent to the vessel wall with a superior imaging quality and, in addition, provided new insights into the stent performance at the open bifurcation site...
  30. ncbi request reprint Use of Taxus polymer-coated paclitaxel-eluting stents for treatment of in-stent restenosis in real world patients: results of clinical and angiographic follow-up at six months in a single-center registry
    Victor Y Lim
    Department of Cardiology and Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 68:343-8. 2006
    ..To evaluate the safety and efficacy of Taxus paclitaxel-eluting stents in a real world group of unselected patients with coronary in-stent restenosis (ISR) lesions...
  31. ncbi request reprint Results of the Jostent coronary stent graft implantation in various clinical settings: procedural and follow-up results
    Ulrich Gercken
    Department of Cardiology and Angiology, Heart Center, Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 56:353-60. 2002
    ..Covered stents such as the JoMed coronary stent graft may become essential for bailout treatment of coronary perforations...
  32. ncbi request reprint Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents
    Eberhard Grube
    Department of Cardiology Angiology, Heart Center Siegburg, Germany
    Herz 29:162-6. 2004
    ....
  33. ncbi request reprint Evaluation of a new polymer-coated paclitaxel-eluting stent for treatment of de novo lesions: six-month clinical and angiographic follow-up results of the APPLAUSE trial
    Eberhard Grube
    Department of Cardiology and Angiology, Heart Center, Siegburg, Germany
    J Invasive Cardiol 18:194-8. 2006
    ..This trial assesses the safety and efficacy of the PicoElite stent (amg International GmbH, Raesfeld-Erle, Germany), a new paclitaxel-eluting polymer-based stent...
  34. ncbi request reprint ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Lutz Buellesfeld
    Department of Cardiology Angiology, Heart Center Siegburg, Germany
    Herz 29:167-70. 2004
    ..If the results of both pivotal studies ENDEAVOR II and III confirm the efficacy of the ENDEAVOR stent design observed so far, the ENDEAVOR stent will be established as a new and promising contender in the field of DES...
  35. doi request reprint Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis
    Lutz Buellesfeld
    Department of Cardiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 71:579-84. 2008
    ..We implanted this prosthesis in a 93-year old patient presenting with severe symptomatic aortic stenosis (valve area: 0.6 cm(2)). Surgical valve replacement had been declined due to comorbidities...
  36. ncbi request reprint Percutaneous aortic valve replacement for severe aortic regurgitation in degenerated bioprosthesis: the first valve in valve procedure using the Corevalve Revalving system
    Peter Wenaweser
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 70:760-4. 2007
    ..We report on the first successful valve in valve procedure in an 80-year-old patient with a severe regurgitation of a degenerated aortic bioprosthesis using the Corevalve Revalving system...
  37. doi request reprint Transaortic transcatheter aortic valve implantation: a novel approach for the truly "no-access option" patients
    George Latsios
    Department of Cardiology and Angiology, Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 75:1129-36. 2010
    ....
  38. ncbi request reprint Volume-outcome relation for contemporary percutaneous coronary interventions (PCI) in daily clinical practice: is it limited to high-risk patients? Results from the Registry of Percutaneous Coronary Interventions of the Arbeitsgemeinschaft Leitende Kardio
    R Zahn
    Kardiologie Angiologie Internistische Intensivmedizin, Klinikum Nürnberg Süd, Nurnberg
    Heart 94:329-35. 2008
    ..The formerly observed volume-outcome relation for percutaneous coronary interventions (PCIs) has recently been questioned...
  39. ncbi request reprint Percutaneous transluminal coronary angioplasty of left main stenosis--results of the German PTCA registry
    S Miketic
    Medizinische Klinik II Klinikum Lippe Detmold
    Z Kardiol 89:508-12. 2000
    ..The risk stratification of the procedure can be evaluated by the proposed grading of left main artery protection...
  40. pmc Incidental finding of a papillary fibroelastoma on the aortic valve in 16 slice multi-detector row computed tomography
    A Bootsveld
    CT MRI Center Siegburg, Germany
    Heart 90:e35. 2004
    ..This report describes the characteristics of a PFE with multidetector 16 slice computed tomography and 1.5 Tesla cardiac magnetic resonance imaging...
  41. ncbi request reprint [Brugada syndrome or ARVD (arrhythmogenic right ventricular dysplasia) or both? Significance and value of right precordial ECG changes]
    Th Schmidt
    Medizinische Klinik Kardiologie Krankenhaus Siegburg Ringstrasse 49 53721 Siegburg, Germany
    Z Kardiol 91:416-22. 2002
    ..As a prognostic indication we decided to implant an ICD prophylactically. The case report demonstrates the value of familiar examination of patients with an unclear ventricular arrhythmogenic event...
  42. doi request reprint Transcatheter aortic valve implantation: first results from a multi-centre real-world registry
    Ralf Zahn
    Abteilung fur Kardiologie, Herzzentrum Ludwigshafen, Bremserstrasse 79, Ludwigshafen, Germany
    Eur Heart J 32:198-204. 2011
    ..We report the first results of the prospective multi-centre German Transcatheter Aortic Valve Interventions-Registry...
  43. ncbi request reprint Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging technique
    Ulrich Gerckens
    Department of Cardiology Angiology, Heart Center, Klinikum Siegburg Rhein Sieg GmbH, Siegburg, Germany
    Herz 28:496-500. 2003
    ..Trials comparing intravascular ultrasound (IVUS) and OCT demonstrated that OCT provided additional morphologic information, which could be used to improve plaque characterization...
  44. ncbi request reprint Everolimus for stent-based intracoronary applications
    Eberhard Grube
    Heart Center Siegburg, Siegburg, Germany
    Rev Cardiovasc Med 5:S3-8. 2004
    ..The everolimus-eluting coronary stent might shortly be established as a new and promising contender in the field of drug eluting stents for treatment of coronary heart disease...
  45. doi request reprint Carotid artery revascularization in high surgical risk patients with the NexStent and the Filterwire EX/EZ: 1-year results in the CABERNET trial
    L Nelson Hopkins
    Department of Neurosurgery, University of Buffalo and Toshiba Stroke Center, Buffalo, New York 14209, USA
    Catheter Cardiovasc Interv 71:950-60. 2008
    ..The multicenter, single-arm CABERNET trial evaluated outcomes in high-surgical-risk patients with carotid artery stenosis treated with the NexStent plus FilterWire EX/EZ Emboli Protection System...
  46. ncbi request reprint Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I)
    Eberhard Grube
    Heart Center Siegburg, Siegburg, Germany
    Am J Cardiol 96:79-82. 2005
    ..The single target vessel revascularization in the TAXUS group was remote from the target lesion in contrast to 3 target lesion revascularizations in the control group...
  47. ncbi request reprint High-frequency mechanical vibration to recanalize chronic total occlusions after failure to cross with conventional guidewires
    Eberhard Grube
    Klinikum Siegburg, Siegburg, Germany
    J Invasive Cardiol 18:85-91. 2006
    ..The objective of the study was to determine whether the CROSSER system could safely cross such CTOs...
  48. doi request reprint Carotid artery revascularisation in high-surgical-risk patients with the NexStent and the FilterWire EX/EZ: 3-year results from the CABERNET trial
    L Nelson Hopkins
    University at Buffalo, NY, USA
    EuroIntervention 5:917-24. 2010
    ..To investigate long-term outcomes achieved in high-surgical-risk patients and other clinically-relevant subgroups after carotid stenting with the NexStent and Filterwire EX/EZ devices...
  49. ncbi request reprint [Background and indications for distal protection devices in percutaneous coronary interventions]
    L Buellesfeld
    HELIOS Klinikum Siegburg, Medizinische Klinik Kardiologie und Angiologie
    Dtsch Med Wochenschr 131:2160-4. 2006
  50. pmc Computerized two-lead resting ECG analysis for the detection of coronary artery stenosis after coronary revascularization
    Eberhard Grube
    Department of Cardiology, Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Int J Med Sci 5:50-61. 2008
    ..We compared a new computer-enhanced, resting ECG analysis device, 3DMP, to coronary angiography to evaluate the device's accuracy in detecting hemodynamically relevant CAD...
  51. ncbi request reprint [Optical coherence tomography imaging in coronary drug-eluting stenting]
    Ulrich Gerckens
    Department of Cardiology Angiology, Heart Center Siegburg, Siegburg, Germany
    Rev Esp Cardiol 58:1469. 2005
  52. ncbi request reprint Initial multicenter experience with a novel distal protection filter during carotid artery stent implantation
    Eberhard Grube
    Heart Center, Siegburg, Germany
    Catheter Cardiovasc Interv 58:139-46. 2003
    ....
  53. pmc Computerized two-lead resting ECG analysis for the detection of coronary artery stenosis
    Eberhard Grube
    Department of Cardiology, Angiology, Heart Center Siegburg, Klinikum Siegburg, Ringstrasse 49, D 53721 Siegburg, Germany
    Int J Med Sci 4:249-63. 2007
    ..We compared a new computer-enhanced, resting ECG analysis device, 3DMP, to coronary angiography to evaluate the device's accuracy in detecting hemodynamically relevant CAD...
  54. ncbi request reprint An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program
    John M Lasala
    Division of Cardiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Interv Cardiol 19:422-31. 2006
    ....
  55. ncbi request reprint Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II
    Sigmund Silber
    Cardiology Practice and Hospital, Munich, Germany
    Herz 29:171-80. 2004
    ..While predilatation was recommended per protocol, direct stenting was not forbidden: thus, direct stenting was performed in 49 patients (TAXUS n = 23, control n = 26)...
  56. ncbi request reprint Angiographic, intravascular ultrasound, and fractional flow reserve evaluation of direct stenting vs. conventional stenting using BeStent2 in a multicentre randomized trial
    William Wijns
    Cardiovascular Centre, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium
    Eur Heart J 26:1852-9. 2005
    ..The objective was to demonstrate equivalence of post-procedural mean luminal diameter (MLD) by angiography after BeStent2 placement between DS and pre-dilatation (PD) strategy...
  57. doi request reprint Impact of mild or moderate renal insufficiency on the intravascular ultrasonic analysis of chronic vascular response to paclitaxel-eluting and bare-metal stents (from the TAXUS IV, V, and VI trials)
    Jiro Aoki
    Columbia University Medical Center, New York, New York, USA
    Am J Cardiol 102:1009-16. 2008
    ..In conclusion, neointimal proliferation was less prominent and expansive vessel remodeling was more prominent after PES than BMS implantation, independent of the severity of renal dysfunction...
  58. doi request reprint Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry)
    Cosmo Godino
    Interventional Cardiology Unit, San Raffaele Institute, Milan, Italy
    Am J Cardiol 102:1002-8. 2008
    ..The rate of subacute and late stent thrombosis was low in this subgroup of patients...
  59. ncbi request reprint Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary beta-radiation therapy
    Peter W Radke
    Medical Clinic I, RWTH University Hospital, Pauwelsstrasse 30, 52057 Aachen, Germany
    Eur Heart J 25:920-5. 2004
    ..This matched-pair analysis compared the procedural and long-term clinical and angiographic outcome after treatment of diffuse ISR using a paclitaxel-eluting stent (PES) with intracoronary beta-radiation therapy...
  60. doi request reprint Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry
    Marco De Carlo
    Cardiothoracic and Vascular Department, University of Pisa, Pisa, Italy
    Catheter Cardiovasc Interv 72:196-203. 2008
    ..The aim of this study was to investigate the safety and efficacy of an innovative thrombectomy device, the Rinspiration System, which simultaneously "rinses" the vessel with turbulent flow and aspirates thrombus...
  61. doi request reprint Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus
    Masashi Kimura
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 101:1263-8. 2008
    ....
  62. ncbi request reprint Treatment of In-Stent restenosis using a stent with non-polymer-based paclitaxel elution
    Rainer Hoffmann
    Medical Clinic I, University Aachen, Aachen, Germany
    Am J Cardiol 93:760-2. 2004
    ..At 6-month follow-up, in-stent late loss was 0.44 +/- 0.54 mm and the restenosis rate was 20%, indicating effective treatment for reduction of recurrent restenosis...
  63. ncbi request reprint Initial and follow-up results of the European Seaquence coronary stent registry
    Martial Hamon
    Service des Maladies du Coeur et des Vaisseaux, Avenue Cote de Nacre, CHU de Caen, 14 033 Caen Cedex, France
    J Interv Cardiol 17:9-15. 2004
    ....
  64. ncbi request reprint Direct stent implantation using the EXPRESS Coronary Stent System: results of a multi-center feasibility study
    Sigmund Silber
    Internistische Klinik Dr Müller, Herzkatheterlabor Cardiology Associates, Munich, Germany
    J Interv Cardiol 16:491-7. 2003
    ..No other MACE were observed during the three-month follow-up period. Based on the findings of this study, direct stenting with the EXPRESS Stent appears feasible and is well tolerated...
  65. ncbi request reprint Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions
    Antonio Colombo
    Ospedale San Raffaele, Milano, Italy
    Circulation 108:788-94. 2003
    ..Early clinical studies demonstrated the feasibility of local paclitaxel delivery in reducing restenosis after treatment of de novo coronary lesions in small patient populations...
  66. ncbi request reprint Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients
    Michael Haude
    Cardiology Clinic, University Essen, Essen, Germany
    Circulation 107:1265-70. 2003
    ..Therefore, we performed this prospective, randomized trial to evaluate the angiographic and clinical outcome after treatment of stenoses in small coronary arteries (2.0 to 2.6 mm) of symptomatic patients...
  67. ncbi request reprint TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation
    Kengo Tanabe
    Division of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    Circulation 107:559-64. 2003
    ..We performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR)...
  68. ncbi request reprint Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction
    Simon R Dixon
    Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA
    J Am Coll Cardiol 40:1928-34. 2002
    ..The purpose of this study was to evaluate the safety and feasibility of endovascular cooling during primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)...
  69. ncbi request reprint [State of treatment of coronary artery disease by drug releasing stents]
    Ralf Muller
    Abteilung für Kardologie, Herzzentrum Siegburg, Germany
    Herz 27:508-13. 2002
    ....
  70. ncbi request reprint 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE)
    Toru Kataoka
    Center for Research in Cardiovascular Interventions, Stanford University, Stanford, Calif 94305, USA
    Circulation 106:1788-93. 2002
    ..The purpose of this substudy was to evaluate the acute expansion property and long-term neointimal responses of qDES compared with BMS as assessed by intravascular ultrasound (IVUS)...
  71. ncbi request reprint Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial
    Patrick W Serruys
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 44:1363-7. 2004
    ..We sought to demonstrate the safety and performance of the actinomycin D-coated Multilink-Tetra stent(Guidant Corp., Santa Clara, California) in the treatment of patients with single de novo native coronary lesions...
  72. ncbi request reprint Clinical experiences using everolimus-eluting stents in patients with coronary artery disease
    Hans Störger
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    J Interv Cardiol 17:387-90. 2004
    ..0001). In FUTURE II, a randomized multi-center study, a total of 64 patients were enrolled confirming safety and feasibility. After 6 months late loss was 0.85 mm in the control group and 0.12 mm in the everolimus group (p < 0.001)...
  73. ncbi request reprint Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials)
    Yoshihiro Tsuchiya
    The Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York, USA
    Am J Cardiol 98:464-9. 2006
    ..The EES appears to be effective for treatment of de novo coronary lesions in decreasing neointimal proliferation at 6-month follow-up compared with BMSs, regardless of vessel size...
  74. ncbi request reprint Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions
    Ricardo A Costa
    The Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York, USA
    Am J Cardiol 98:443-6. 2006
    ..14 +/- 0.45 vs 0.40 +/- 0.41 mm, p = 0.004). In-stent restenosis was 3.9% in the Biolimus stent group versus 7.7% in the control group (p = 0.40). There was no exaggerated hyperplasia at the proximal and/or distal edge of the stent...
  75. ncbi request reprint Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 356:998-1008. 2007
    ..Such studies have been inconclusive because of their insufficient size, the use of historical controls, a limited duration of follow-up, and a lack of access to original source data...
  76. ncbi request reprint Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1043-51. 2007
    ..This study sought to study stent thrombosis with the paclitaxel-eluting Taxus stent...
  77. ncbi request reprint Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials
    Neil J Weissman
    Cardiac Ultrasound and Ultrasound Core Laboratory, Cardiovascular Research Institute Medstar Research Institute, Washington Hospital Center, 100 Irving Street, NW, Suite EB 5123, Washington, DC 20010, USA
    Eur Heart J 28:1574-82. 2007
    ..Since intravascular ultrasound (IVUS) methodology and core laboratory were consistent among all three TAXUS trials, an integrated analysis of 956 patients across all IVUS cohorts can be performed providing superior power...
  78. ncbi request reprint Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials
    Jeffrey W Moses
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 47:2164-71. 2006
    ....
  79. ncbi request reprint Influence of plaque calcium on neointimal hyperplasia following bare metal and drug-eluting stent implantation
    Yoshihisa Shimada
    The Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    Catheter Cardiovasc Interv 67:866-9. 2006
    ..To examine the influence of vessel wall calcium on neointimal hyperplasia (NIH) following bare metal stent (BMS) and drug-eluting stent (DES) implantation...
  80. ncbi request reprint Meta-analysis of angiographic versus intravascular ultrasound parameters of drug-eluting stent efficacy (from TAXUS IV, V, and VI)
    Esteban Escolar
    Cardiovascular Research Institute Medstar Research Institute, Washington Hospital Center, Washington, DC, USA
    Am J Cardiol 100:621-6. 2007
    ..91 and p <0.001. In conclusion, the QCA and IVUS parameters used to evaluate drug-eluting stent efficacy showed a moderate correlation with IVUS percentage of intimal hyperplasia, reliably predicting QCA binary in-stent restenosis...
  81. ncbi request reprint Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study
    Giuseppe G L Biondi-Zoccai
    Int J Cardiol 108:406-7. 2006
    ..These findings thus support the overall safety and effectiveness of ticlopidine after DES implantation, and also confirm the increased risk of late thrombosis when premature withdrawal of thienopyridines occurs...
  82. ncbi request reprint Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial
    Alexandre Abizaid
    Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
    Catheter Cardiovasc Interv 70:654-60. 2007
    ....
  83. ncbi request reprint Acute and long-term outcomes of the novel side access (SLK-View) stent for bifurcation coronary lesions: a multicenter nonrandomized feasibility study
    Fumiaki Ikeno
    Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA
    Catheter Cardiovasc Interv 67:198-206. 2006
    ..To evaluate technical feasibility and procedural safety of SLK-View stent for treating bifurcation lesions...
  84. ncbi request reprint Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice
    Keith D Dawkins
    Southampton University Hospital, Southampton, UK
    Circulation 112:3306-13. 2005
    ..Intracoronary polymer-based stent delivery of paclitaxel has been shown to be effective in reducing restenosis in simple coronary lesions, but the evidence base for contemporary use in longer, more complex coronary stenoses is lacking...
  85. ncbi request reprint Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial
    Akiyoshi Miyazawa
    Stanford University Medical Center, Stanford, CA 94305 5637, USA
    Catheter Cardiovasc Interv 70:952-7. 2007
    ..The aim of this intravascular ultrasound (IVUS) study was to assess the efficacy of the AXXESS Plus stent system for the treatment of bifurcation coronary lesions...
  86. ncbi request reprint Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions
    Alberto Fonseca
    Instituto Dante Pazzanese de Cardiologia, Sao Paulo SP, Brasil
    J Invasive Cardiol 20:21-7. 2008
    ..We sought to investigate the safety, feasibility and mechanism of action of a new scoring-balloon catheter, the AngioSculpt, comprised of a semicompliant balloon and a nitinol spiral cage designed to address complex lesions...
  87. ncbi request reprint Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement
    Franz Josef Neumann
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    Circulation 111:2107-11. 2005
    ..This study sought to assess the effectiveness and safety of the sirolimus-eluting stent in the treatment of in-stent restenosis...
  88. doi request reprint Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data)
    Gregg W Stone
    The Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 102:1017-22. 2008
    ....